Drug notes:
SRK-181 Clin1 immuno-oncology; 2 undisclosed programs RD/Clin0 anemia, fibrosis
About:
Scholar Rock is discovering new medicines that target inactive forms of growth factors to treat disease. Growth factors in their active form are common therapeutic targets, since they are extracellular and drivers of disease. However, many mature, active forms of different growth factors are structurally similar, limiting drug specificity. Scholar Rock is targeting the inactive precursor, or latent, forms of growth factors to regulate their activity in the tissue microenvironment. To identify therapeutics, Scholar Rock is using their proprietary platform to develop antibody drugs that recognise the prodomain of precursor growth factors. Scholar Rock’s lead candidate, Apitegromab, is in Phase 3 clinical trials for patients with Spinal Muscular Atrophy.
Jobs:
Area Business Director (East) Remote|3 days ago
Area Business Director (Midwest) Remote|3 days ago
Area Business Director (West) Remote|3 days ago
Manager/Sr. Manager, Quality Control Cambridge, MA|6 days ago
Director, Digital Marketing Cambridge, MA|13 days ago
Associate Director, Clinical Sciences Remote|17 days ago
Director/Senior Director, Pricing, Contracting &am... Remote|17 days ago
Senior Director, Financial Planning & Analysis... Cambridge, MA|17 days ago
Director/ Sr. Director, Early Pipeline Commerciali... Cambridge, MA|17 days ago
Senior Director, Global Marketing Remote|33 days ago
Senior Manager, Regulatory Operations Cambridge, MA|34 days ago
Director, Value & Access Strategy Cambridge, MA|42 days ago
Sr. Director, Supply Chain and Demand Planning Cambridge, MA|45 days ago
Senior Director, Market Insights Cambridge, MA|46 days ago
Associate Director, Commercial & Medical Appli... Cambridge, MA|46 days ago
Director of Corporate & Business Development (... Cambridge, MA|49 days ago
Director of Corporate & Business Development (... Cambridge, MA|52 days ago
US Head of Medical Affairs Cambridge, MA|100+ days ago